A SIMPLE KEY FOR ABT-737 UNVEILED

There have been no clinically important distinctions within the pharmacokinetics of possibly midazolam (CYP3A4 substrate) or repaglinide (CYP2C8 substrate) when used concomitantly with finerenone. Many doses of 40 mg finerenone at the time-every day experienced no clinically related effect on AUC or Cmax in the BCRP and OATP substrate rosuvastatin.